Phathom Pharmaceuticals — Third Quarter 2026 Earnings Summary

Phathom Pharmaceuticals reported third-quarter 2026 net revenues of $84.7 million, representing a 71% increase year-over-year and generating positive operating cash flow for the second consecutive quarter. The company reached a milestone of over 2 million total VOQUEZNA prescriptions filled since launch, with approximately 380,000 prescriptions filled during the quarter. Financial results showed a net loss of $13.9 million, while non-GAAP adjusted net income was $3.0 million, driven by disciplined expense management and continued commercial growth. The company reaffirmed its full-year 2026 financial guidance, projecting net revenues between $310 million and $325 million.